Revolution Medicines, Inc.
RVMD
$39.13
$0.010.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -95.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -95.16% |
| Cost of Revenue | 37.72% | 40.86% | 67.17% | 71.18% | 106.54% |
| Gross Profit | -38.47% | -40.86% | -234.60% | -90.56% | -167.42% |
| SG&A Expenses | 51.33% | 54.45% | 48.30% | 72.70% | 70.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.35% | 42.57% | 39.09% | 71.42% | 101.49% |
| Operating Income | -40.02% | -42.57% | -43.98% | -87.42% | -150.35% |
| Income Before Tax | -21.17% | -39.17% | -35.54% | -70.35% | -184.64% |
| Income Tax Expenses | -319.53% | -- | -- | -- | 378.86% |
| Earnings from Continuing Operations | -20.45% | -44.13% | -35.54% | -70.35% | -185.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.45% | -44.13% | -35.54% | -70.35% | -185.87% |
| EBIT | -40.02% | -42.57% | -43.98% | -87.42% | -150.35% |
| EBITDA | -40.11% | -42.69% | -44.12% | -88.35% | -152.80% |
| EPS Basic | 2.13% | 5.64% | 12.28% | 1.94% | -80.53% |
| Normalized Basic EPS | -16.96% | 8.89% | 12.28% | 4.30% | -51.31% |
| EPS Diluted | 2.13% | 5.64% | 12.28% | 1.94% | -80.53% |
| Normalized Diluted EPS | -16.96% | 8.89% | 12.28% | 4.30% | -51.31% |
| Average Basic Shares Outstanding | 23.07% | 52.74% | 54.51% | 73.71% | 58.35% |
| Average Diluted Shares Outstanding | 23.07% | 52.74% | 54.51% | 73.71% | 58.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
